|
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange On Which Registered
|
||
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
NovaBay Pharmaceuticals, Inc.
|
|||
By:
|
/s/ Justin Hall
|
||
Justin Hall
|
|||
Chief Executive Officer and General Counsel
|
Document And Entity Information |
Jul. 06, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | NovaBay Pharmaceuticals, Inc. |
Document, Type | 8-K |
Document, Period End Date | Jul. 06, 2023 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-33678 |
Entity, Tax Identification Number | 68-0454536 |
Entity, Address, Address Line One | 2000 Powell Street, Suite 1150 |
Entity, Address, City or Town | Emeryville |
Entity, Address, State or Province | CA |
Entity, Address, Postal Zip Code | 94608 |
City Area Code | 510 |
Local Phone Number | 899-8800 |
Title of 12(b) Security | Common Stock |
Trading Symbol | NBY |
Security Exchange Name | NYSE |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0001389545 |
RHY_U=3_ 102P,$% @ #HCG M5I>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5 MN %(MB6/: (7->=I3W; M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II% MR=.B':5_'36TGHX-R#8._AE8P=S8\?=_<# M4$L#!!0 ( Z(YU8D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% M 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF& M!KS2O6H0DBBZ0=@S9)[NF:*/Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1, MPFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP M>'3^ 5!+ P04 " .B.=699!YDAD! #/ P $P %M#;VYT96YT7U1Y M<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[: M2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)* MM9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO. M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( Z(YU8'04UB@0 +$ M 0 " 0 !D;V-0 &UL4$L! A0#% M @ #HCG5ADG6TSM *P( !$ ( !KP &1O8U!R;W!S M+V-O &UL4$L! A0#% @ #HCG5IE &PO=V]R:W-H965T &UL4$L! A0#% @ #HCG5I^@&_"Q @ X@P T M ( !CPP 'AL+W-T>6QE &PO=V]R:V)O M;VLN>&UL4$L! A0#% @ #HCG5B0>FZ*M ^ $ !H M ( !P1$ 'AL+U]R96QS+W=O 9(9 0 SP, !, ( !IA( %M#;VYT96YT7U1Y ><&5S72YX;6Q02P4& D "0 ^ @ \!, end
@1W6